SpectRx cancer assay
This article was originally published in The Gray Sheet
Executive Summary
Pivotal clinical trials for the non-invasive cervical cancer detection device will begin by early 2003, SpectRx announces April 15. Clinical results indicate that the third-generation device detects 17% more high-grade pre-cancer compared to thin-layer Pap tests and 28% more than traditional Pap tests. The device also boasts a sensitivity of 92% and specificity of 80%, versus sensitivity of 76% and specificity of 80% for the thin-layer Pap test when compared to colposcopy and histopathology, the firm claims (1"The Gray Sheet" April 17, 2000, p. 18)...